Navigation Links
Non-alcoholic steatohepataitis (NASH) Pipeline Analysis
Date:2/24/2017

NEW YORK, Feb. 23, 2017 /PRNewswire/ -- Non-alcoholic steatohepataitis (NASH) Pipeline Analysis" gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report also covers some of the hot targets in research for NASH treatments and NASH related biomarkers.

Read the full report: http://www.reportlinker.com/p04719470-summary/view-report.html

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Non-alcoholic steatohepataitis (NASH) drugs market. The report also provide strategic insights on some of the molecules that are yet to be launched in the next few years.

Some of the key sections covered in the report are given below:
Epidemiology
In this section, epidemiology of NASH is reviewed to understand potential significance and impact of the disease.

Global & US prevalence rates
Hot Targets, Mechanisms & Therapies
In this section, various NASH associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for NASH along with disease progression biomarkers associated with NASH (Inflammatory, apoptosis, fibrosis)

Market analysis
In market analysis section, global NASH drugs market is indicated along with the estimated Peak sales ($) of leading clinical stage drugs forecasted from 2019-2025.

Forecasting model for NASH market
NASH market dynamics
NASH Market and estimated Peak sales of 8 clinical candidates (OCA-Intercept, Aramchol-Galmed, GR-MD-02-Gilead, Cenicriviroc-Tobira, Simtuzumab-Gilead, Remo Biphasic-Avolynt, IVA 337-Inventiva Pharma, GFT505-Genfit)
NASH related deals analysis with financials (upfront, milestones and royalties)
Funding scenario in NASH market

Pipeline Analysis
Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development)

Pipeline analysis by modalities
Monoclonal Antibodies pipeline analysis
RNA-therapeutics pipeline analysis
Recombinant protein pipeline analysis
Pipeline analysis by leading players & Target analysis
Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic & Metabolic)

Key Players Analysis
The key player's analysis section provides an in-depth understanding of various companies working on Nonalcoholic steatohepatitis (NASH) and their Pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Global key players overview
Global key players Pipeline data (Discovery, Pre-clinical & Clinical development)
Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)

Read the full report: http://www.reportlinker.com/p04719470-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/non-alcoholic-steatohepataitis-nash-pipeline-analysis-300413100.html


'/>"/>
SOURCE Reportlinker
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Tobira Therapeutics Doses First Patient in CENTAUR, A Phase 2b Study of Cenicriviroc in Patients with Non-Alcoholic Steatohepatitis
2. Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
3. New Emergence of Potential Tx & Dx Options Predicted to Transform the Current Landscape for Liver Diseases (NASH) to a $35 Billion Opportunity
4. Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) - Research Report, 2013 - 2020
5. Dermatology Therapeutics Drug Development Pipeline Review, 2016: Approximately One-Third of the US Population Suffers from at Least One Active Skin Condition - Research and Markets
6. Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline
7. Phylogica Ltd - Product Pipeline Review - 2016
8. Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016
9. Quark Pharmaceuticals Inc - Product Pipeline Review - 2016
10. Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2016
11. Wilson Disease - Pipeline Review, H2 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... Fix Inc. (" Fortuna "), a private, clinical-stage biotech ... need for embryonic and fetal stem cells by using direct ... Fortuna announced today the launch of its Scientific ... PhD; Father Kevin FitzGerald , S.J., PhD; Col. (R) ... Giordano , PhD. "We are excited and honored ...
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... Company, and STI Technologies Limited to lower diabetes healthcare ... Through STI,s innoviCares card, which is available throughout all ... DarioHealth customers will be eligible for additional savings when ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... ... Axiad IDS , a leading provider of trusted identities for enterprise, ... a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor in ... address potential cybersecurity threats before they happen. The annual list of top ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National ... is pleased to announce the organization’s Certified Strength Coach credential has earned accreditation ... Coach (CSC) program validates the competency of qualified candidates for jobs in the ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment option ... and elastin in their face, neck, and body through a virtually pain-free, non-surgical ...
Breaking Medicine News(10 mins):